Back to search results
NCT06900023

The BEACON Trial: Diagnostic Tools for Breast Lymphedema After Treatment for Breast Cancer

Enrolling by Invitation
Not specifiedAges 18+Observational
Massachusetts General Hospital
~30 participants
Updated 2025-07-16 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tissue Dielectric Constant
Measured over Baseline
+1 more outcome measured

Conditions

Breast Edema
Breast Lymphedema
Lymphedema, Breast Cancer
Lymphedema

Explore related trials

Breast CarcinomaBreast LymphomaEdema of breast

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Cheryl Brunelle, MScPT · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be a female between the ages of 18 and 85 years.
Have undergone breast conserving surgery +/- LN removal (sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
Have no residual cancer in the breast after definitive breast surgery
Have been treated with radiation therapy and have completed breast cancer treatment (excluding Herceptin and hormonal treatments) at MGH greater than or equal to 3 months ago.
Be able to read and understand English
Understand the proposed study and be willing and fully able to comply with the study procedures
Be a willing participant and be capable of giving and has given informed written consent for entry into the study

Exclusion

Have bilateral BC
Have metastatic or inflammatory BC
Will be excluded from the SOZO measurement of the study if they have implanted cardiac devices or neurostimulators
Have any medical condition that may result in breast swelling;
Uncontrolled congestive cardiac failure,
Arteriovenous haemodialysis,
Current infection or cellulitis of either breast.
Be pregnant or currently breast feeding.
Have a known over-active thyroid or known benign thyroid tumour

What this trial measures

  • Tissue Dielectric ConstantBaseline

    A TDC interbreast ratio ≥ 1.28 in any quadrant will be used as an indicator of breast lymphedema

  • Breast UltrasoundBaseline

    Skin thickness \>1.60 mm in superior and lateral quadrants, \>2.0 mm in the medial and inferior quadrants will be used as an indicator of breast lymphedema.